

Appl. No. 10/001,221
Amtd. dated April 3, 2006
Amendment After Final
Examining Group 1643

PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-68. (Canceled)

69. (Currently Amended) A pharmaceutical composition comprising viral murine cytomegalovirus chemokine 2 (vMCK-2) and an antigen.

70. (Previously Presented) The pharmaceutical composition of claim 69, further comprising a pharmaceutically acceptable excipient.

71. (Previously Presented) The pharmaceutical composition of claim 69, further comprising an adjuvant.

72. (Previously Presented) The pharmaceutical composition of claim 69, further comprising an additional chemokine.

73-74. (Canceled)

75. (Previously Presented) The pharmaceutical composition of claim 69, wherein the chemokine and antigen are linked.

76. (Withdrawn) The pharmaceutical composition of claim 69, wherein the antigen is derived from a microbial pathogen.

77. (Withdrawn) The pharmaceutical composition of claim 76, wherein the microbial pathogen is a bacterium.

78. (Withdrawn) The pharmaceutical composition of claim 76, wherein the microbial pathogen is a virus.

Appl. No. 10/001,221
Amdt. dated April 3, 2006
Amendment After Final
Examining Group 1643

PATENT

79. (Previously Presented) The pharmaceutical composition of claim 69, wherein the composition is encapsulated in a liposome.

80. (Previously Presented) The pharmaceutical composition of claim 69, wherein the composition is encapsulated in a microsphere.

81. (Previously Presented) The pharmaceutical composition of claim 69 which is sterile.

82. (Previously Presented) The pharmaceutical composition of claim 81, wherein the composition is suitable for peritoneal administration.

83. (Previously Presented) The pharmaceutical composition of claim 81, wherein the composition is formulated for administration by injection.

84. (Previously Presented) The pharmaceutical composition of claim 81, wherein the composition is formulated for administration by inhalation.

85. (Previously Presented) The pharmaceutical composition of claim 81, wherein the composition is formulated for topical application.

86. (Previously Presented) The pharmaceutical composition of claim 81, wherein the composition is formulated for oral administration.

87. (Previously Presented) The pharmaceutical composition of claim 81, wherein the composition is formulated for administration by suppository.

88. (Previously Presented) The pharmaceutical composition of claim 69, wherein the antigen is a tumor-associated antigen.

89. (Previously Presented) A pharmaceutical composition comprising mC10 and an antigen.

Appl. No. 10/001,221
Amdt. dated April 3, 2006
Amendment After Final
Examining Group 1643

PATENT

90. (Previously Presented) The pharmaceutical composition of claim 89, further comprising a pharmaceutically acceptable excipient.

91. (Previously Presented) The pharmaceutical composition of claim 89, further comprising an adjuvant.

92. (Previously Presented) The pharmaceutical composition of claim 89, further comprising an additional chemokine.

93. (Previously Presented) The pharmaceutical composition of claim 89, wherein the chemokine and antigen are linked.

94. (Withdrawn) The pharmaceutical composition of claim 89, wherein the antigen is derived from a microbial pathogen.

95. (Withdrawn) The pharmaceutical composition of claim 94, wherein the microbial pathogen is a bacterium.

96. (Withdrawn) The pharmaceutical composition of claim 94, wherein the microbial pathogen is a virus.

97. (Previously Presented) The pharmaceutical composition of claim 89, wherein the composition is encapsulated in a liposome.

98. (Previously Presented) The pharmaceutical composition of claim 89, wherein the composition is encapsulated in a microsphere.

99. (Previously Presented) The pharmaceutical composition of claim 89 which is sterile.

100. (Previously Presented) The pharmaceutical composition of claim 99, wherein the composition is suitable for peritoneal administration.

Appl. No. 10/001,221
Amdt. dated April 3, 2006
Amendment After Final
Examining Group 1643

PATENT

101. (Previously Presented) The pharmaceutical composition of claim 99, wherein the composition is formulated for administration by injection.

102. (Previously Presented) The pharmaceutical composition of claim 99, wherein the composition is formulated for administration by inhalation.

103. (Previously Presented) The pharmaceutical composition of claim 99, wherein the composition is formulated for topical application.

104. (Previously Presented) The pharmaceutical composition of claim 99, wherein the composition is formulated for oral administration.

105. (Previously Presented) The pharmaceutical composition of claim 99, wherein the composition is formulated for administration by suppository.

106. (Previously Presented) The pharmaceutical composition of claim 89, wherein the antigen is a tumor-associated antigen.